*W.Y.W and X.Q.M contributed equally to this work.
Introduction
Morphine is a good choice for managing moderate-to-severe pain, providing effective pain relief. However, its side effects, especially the development of tolerance, cannot be underestimated. Although many mechanisms have been implicated in the development of the analgesic tolerance elicited by prolonged morphine administration (Bekhit, 2010) , the neurotransmitters/receptors involved are still unclear.
The purinergic P2X3 receptor, one of the seven members of the ionotropic P2X receptor family, is highly expressed in small-diameter sensory neurons of the dorsal root ganglia (DRGs) and have been reported to be involved in both acute (Souslova et al., 2000) and chronic pain (Jarvis et al., 2002) . Antagonists of P2X3 receptor have been reported to attenuate inflammatory and neuropathic pain when used systemically (Jarvis et al., 2002) and locally (McGaraughty et al., 2003) . Since the processes by which both morphine tolerance and chronic pain may share common pathways (Mayer et al., 1999) , in a previous study, we investigated the involvement of P2X3 receptor in the development of morphine antinociceptive tolerance and showed that A317491, a P2X3 antagonist, not only partially prevents the development of morphine anti-nociceptive tolerance but also potently reverses the tolerance established by bolus administration in mice . Here, we explored the detailed mechanisms involving P2X3 receptor in morphine-induced antinociceptive tolerance.
Methods

Animals
Adult male Sprague-Dawley rats (Fudan University Medical Animal Center, Shanghai, China) weighing 200-250 g were housed in groups of five in cages (64 × 40 × 22 cm) before cannulation and housed individually after cannulation with a chew stick and nesting material for environmental enrichment. All the animals were housed on corn cob in a room maintained at a constant temperature of 22-23°C with an alternating 12 h light/dark cycle (lights on at 07:00 h) with water and food available ad libitum. In all behavioural experiments, six rats were included in each group. The protocol followed the NIH Guide for the Care and Use of Laboratory Animals (1996) and was approved by the Animal Care and Use Committee of the Sixth People's Hospital Affiliated to Shanghai Jiao Tong University [SYXK (Shanghai, China) 2011-0128, 1 January 2011]. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley, 2015) . All efforts were made to minimize suffering and reduce the number of animals used. The overall experimental design is illustrated in Figure 2A .
Intrathecal cannulation
For repeated delivery of drugs, i.t. cannulation was performed using the method described by Storkson et al. (1996) . Briefly, animals were anaesthetized with isoflurane inhalation in 100% oxygen (induced at 5% and maintained at 2%), then an 8 cm PE-10 catheter (Becton Dickinson, Sparks, MD, USA) was inserted into the subarachnoid space at the L4-L5 level. During surgery, the concentration of isoflurane was increased when necessary. Involuntary movements of the tail or hindlimb were regarded as signs of dura penetration. The catheter was then advanced 1 cm into the i.t. space to reach the level of the lumbar enlargement. The external end of the catheter was sealed by heat. The correct location of the catheter was verified by i.t. injection of lidocaine (2%, 10 μL) on the next day, which caused reversible bilateral hindlimb paresis for 10-15 min. The rats were allowed to recover for 3 days before drug administration; penicillin was administered to prevent infection.
Drugs and groups
Rats were briefly anaesthetized with isoflurane to isolate the i. t. catheter; following recovery, they were placed in a transparent Plexiglas box, and drugs were slowly (1 μL·min À1 )
injected through the exteriorized portion of the catheter with a micro-syringe (Hamilton, Reno, NV, USA) in a 10 μL volume followed by a flush with 10 μL of 0.9% saline (Baxter Healthcare, New York, NY, USA). Successfully catheterized rats were treated randomly with i.t. morphine (15 μg in 10 μL saline; Shenyang First Pharmaceutical Factory, Shenyang, China) for 3, 5 and 7 days; morphine plus A317491 (15 μg in 10 μL saline; Sigma, St. Louis, MO, USA) or A-317491 alone for 7 days; morphine plus the PKCε inhibitor ε-V1-2 (10 μg in 10 μL saline; AnaSpec Inc., Fremont, CA, USA) or ε-V1-2 alone for 7 days; morphine plus the exchange factor directly activated by cAMP (Epac) inhibitor ESI-09 (5 μg in 10 μL 20% DMSO; Sigma) or ESI-09 alone for 7 days; or saline control for 7 days. The inhibitors were given 30 min before morphine treatment.
Behavioural tests
Paw-withdrawal test. Rats were habituated to the experimental conditions for 4 days before experiments. Paw pressure thresholds were assessed using a paw pressure analgesia meter (Ugo Basile, Varese, Italy) before and 30 min after i.t. injection. The cut-off threshold was set at 250 g. The paw pressure thresholds were determined by averaging three consecutive trials separated by 5 min.
Tail-flick latency. The pain response to thermal stimuli was assessed using a Tail-Flick Analgesia Meter (Columbus Instruments, Columbus, OH, USA). In brief, radiant heat was applied to the animal's tail~4 cm from the tip. The intensity of the thermal stimulus was adjusted to provide an average baseline tail-flick latency of 3-4 s. A cut-off time of 10 s was set to avoid injury. Only rats with baseline reaction times between 3 and 4 s were used in experiments. The control reaction time and the latency of the response were recorded twice, with an interval of 15 min between readings.
Western blotting
Under deep anaesthesia with pentobarbital (50 mg·kg À1 , i.p.)
and hypoxia with carbon dioxide, the L4-L5 DRGs were removed and immediately homogenized in ice-chilled tissue protein extraction reagent. Samples were prepared as reported previously 
Immunohistochemistry
For fluorescence immunohistochemistry, rats were anaesthetized with pentobarbital (50 mg·kg À1 , i.p.) and made hypoxic with carbon dioxide and transcardially perfused with 4% cold paraformaldehyde. DRGs were harvested, post-fixed for 4 h at 4°C in 4% paraformaldehyde and then dehydrated sequentially in 10, 20 and 30% sucrose overnight for 3 days. Frozen sections (10 μm) were cut on a cryostat and air dried on microscope slides for 30 min at room temperature before use. In all groups, double labelling was used to assess the colocalization of P2X3 receptor with ionized Ca 2+ -binding adapter molecule 1, isolectin B4 (IB4), neurofilament 200 (NF200), peripherin, PKCε or Epac in the DRGs. Frozen sections were prepared as previously reported , and the slides were incubated with the primary antibody (rabbit anti-P2X3 receptor, 1:500; mouse anti-PKCε, 1:50, Santa Cruz; mouse anti-rat Epac, 1:50, Santa Cruz; mouse anti-peripherin, 1:100, Millipore, Billerica, MA, USA; mouse anti-NF200, 1:100, Sigma; or FITC-conjugated IB4, 2 μg·mL À1 , Sigma) overnight at 4°C. Subsequently, the slides were rinsed in PBS and incubated with the secondary antibody for 2 h at room temperature. The secondary antibodies goat antimouse IgG H&L (Alexa Fluor ® 594; 1:500) and goat antirabbit IgG H&L (Alexa Fluor 488; 1:500) were from Abcam. Images were acquired using an inverted microscope (Leica DM IL LED, Leica Microsystems, Buffalo Grove, IL, USA).
Statistical analysis
The data and statistical analysis comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . All data are presented as the mean ± SEM and were analysed with Graph-Pad Prism 5 (Graph Pad Software, San Diego, CA, USA). Behavioural data were converted to a percentage maximum possible effect (MPE) as follows: %MPE = 100 × (post-drug latency/threshold À pre-drug latency/threshold) (cut-off latency/threshold À pre-drug latency/threshold). Pawwithdrawal thresholds and tail-flick latencies were analysed using two-way (time and treatment) ANOVA followed by one-way ANOVA (at each time point) and Tukey's test for multiple comparisons. To control for unwanted sources of variation, the relative expression of target proteins in different groups was normalized to GAPDH, and the phosphorylation level of target proteins was compared with their total level. We set the average value of the saline group to 1 and standardized each set of data. The value of each group including the saline control group was normalized to the mean value of the saline group (Park et al., 2013; Chu et al., 2014) . The Kolmogorov-Smirnov test showed the data followed Gaussian distribution. If data follow Gaussian distribution, one-way ANOVA (protein levels) or Student's t-test (number of positive cells) was carried out. Post hoc tests were run only when F achieved P < 0.05. If data were not normally distributed, nonparametric tests were used. Differences were considered significant at P < 0.05. Behavioural tests, cell counting, protein quantitation and all data analyses were performed by observers who were blinded to the experimental groups.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
Chronic morphine treatment induces P2X3 receptor expression
Western blot analyses were used to determine the effect of repeated morphine treatment on P2X3 receptor expression in the DRG ( Figure 1A) . Analysis of the time course revealed that such treatment for 5 or 7 days increased the P2X3 receptor expression by 1.91 ± 0.33-and 2.16 ± 0.24-fold compared with the saline group ( Figure 1A , P < 0.05). The number of P2X3 receptor-positive cells in DRGs after morphine treatment increased by 2.15 ± 0.59-fold compared with control ( Figure 1B , P < 0.05).
A-317491 diminishes the degree of morphine-induced anti-nociceptive tolerance
The overall experimental design was shown in Figure 2A . Repeated i.t. administration of morphine-induced acute increases in both tail-flick latency to thermal stimulation ( Figure 2B ) and paw-withdrawal threshold to mechanical stimulation ( Figure 2C ) on days 1 to 3 (P < 0.05 vs. saline group). In thermal nociceptive testing ( Figure 2B ), morphine-induced antinociceptive efficacy was attenuated through days 4 to 7 in the morphine-alone group (%MPE 17.1 ± 3.1 on day 7, P > 0.05 vs. saline group), while in the A317491 plus morphine group, the analgesic potency of morphine was still powerful on day 7 (%MPE 69.8 ± 6.8, P < 0.05 vs. saline group). Daily A317491 injection partially prevented the morphine-induced antinociceptive tolerance throughout the 7 days. In mechanical threshold testing ( Figure 2C ), the efficacy of morphine declined to the baseline level (%MPE 11.8 ± 2.4) in the morphine-alone group on day 7 (P > 0.05). On days 4 to 7, the morphine-induced analgesia in the morphine-alone group showed a markedly decreasing mechanical threshold compared with the saline group. However, the degree of tolerance was diminished by daily injection of A317491 and morphine through day 7 (%MPE 82.2 ± 5.4, P < 0.05 vs. saline and morphine groups).
Assessment of morphine potency 24 h after the chronic tolerance protocol (only morphine was given in the dose-response test on day 8) revealed a rightward shift in the dose-response curve in rats that had been repeatedly given morphine compared with those given saline. A317491 prevented the rightward shift in tail-flick assays (Supporting Information Figure S1A ). Calculation of the morphine ED 50 from the dose-response curves revealed that rats receiving morphine alone had higher values [17.84 to 23.51, 95% confidence interval (CI)] in the tail-flick test than animals that had received saline (0.87 to 1.16, 95% CI), morphine with A-317491 (2.25 to 2.69, 95% CI) or A-317491 alone (0.90 to 1.34, 95% CI) (P < 0.05 for all), suggesting that A-317491 prevents the decline in morphine potency (Supporting Information Figure S1B ). There was no difference in the morphine ED 50 values for morphine plus A-317491, A-317491 alone and saline (Supporting Information Figure S1B ).
Co-localization of P2X3 receptor with IB4 and peripherin
P2X3 receptor were strongly co-localized with IB4, a marker of non-peptidergic C-fibre neurons ( Figure 3B ). Higher magnification images of DRG sections from morphine-tolerant rats showed that P2X3 receptor were localized in the entire cytoplasm ( Figure 3D ). We also confirmed that P2X3 receptor did not co-localize with microglia ( Figure 3A ) or astrocytes (data not shown). The majority of P2X3 receptor were colocalized with peripherin, a marker of neurons with unmyelinated or small-calibre fibres (Figure 3D) , and a minority was co-localized with NF200, a marker of neurons with myelinated fibres ( Figure 3C ).
Pharmacological inhibition of phosphorylation of PKCε prevents morphine anti-nociceptive tolerance and suppresses chronic morphine-induced P2X3 receptor expression
To identify the contributors to the increased P2X3 receptor expression in the DRGs after chronic morphine treatment, we assessed the phosphorylation of the possible upstream regulator, PKCε, and determined whether its inhibition reduces the chronic morphine-induced P2X3 receptor expression and relieves morphine tolerance. We found that the phosphorylation of PKCε had the same pattern as the P2X3 receptor expression after chronic morphine exposure: morphine treatment for 3, 5 or 7 days increased PKCε phosphorylation by 1.94 ± 0.42-fold, 2.99 ± 0.56-fold and 3.19 ± 0.39-fold compared with the saline group ( Figure 4A , P < 0.05). Although morphine markedly increased the threshold on day 1, the anti-nociception effect was reduced within 3 days of treatment, and by day 7, morphine had no effect ( Figures 4D and 5D ), demonstrating the development of antinociceptive tolerance. Co-administration of the PKCε-selective inhibitor ε-V1-2 with morphine for 7 consecutive days greatly suppressed the morphine-induced expression of P2X3 receptor ( Figure 4B , P < 0.05 vs. morphine group), while the anti-nociceptive effect of morphine remained throughout the treatment ( Figure 4D , P < 0.05). ε- Figure 1 (A) Expression of P2X3 receptor and (B) number of P2X3 receptor-positive cells per section per animal in DRGs increase after repeated morphine treatment. The DRGs were removed 2 h after morphine injection on day 7 (n = 6,*P < 0.05 vs. saline (S) group). M3, 3 days of morphine injection; M5, 5 days of morphine injection; M7, 7 days of morphine injection. V1-2 alone had no effect on the mechanical threshold and P2X3 receptor expression. Double-labelling immunofluorescence showed clear co-localization of P2X3 receptor and PKCε in the same DRG neurons ( Figure 4C ). Bolus ε-V1-2 injection (10 μg, i.t.) tended to potentiate the morphineinduced anti-nociception in morphine-tolerant rats on day 8, although the difference did not reach statistical significance (Supporting Information Figure S2 , P > 0.05 vs. day 7 morphine-induced anti-nociception).
Inhibition of Epac prevents morphine anti-nociceptive tolerance and suppresses both P2X3 receptor expression and PKCε phosphorylation after chronic morphine treatment
To further explore the mechanism of increased P2X3 receptor expression after prolonged morphine exposure, we evaluated the effect of ESI-09 (an Epac inhibitor) on the expression of P2X3 receptor and PKCε phosphorylation. Chronic morphine treatment time dependently increased the expression of Epac ( Figure 5A , P < 0.05 vs. saline group), indicating its involvement in morphine-induced tolerance. Co-treatment with the Epac inhibitor ESI-09 and morphine reversed the increase in P2X3 receptor and PKCε phosphorylation after chronic morphine injection ( Figure 5B , P < 0.05 vs. morphine group). Furthermore, ESI-09 markedly attenuated the development of morphine-induced anti-nociceptive tolerance, while the anti-nociceptive effect of morphine was retained ( Figure 5D , P < 0.05). The immunofluorescence results showed typical co-localization of P2X3 receptor with Epac ( Figure 5C ).
Discussion
Consistent with our previous work in mice , we found that administration of the selective P2X3 receptor antagonist A317491 attenuated the morphine-induced anti-nociceptive tolerance in rats. Co-localization of P2X3 receptor with IB4 and peripherin showed that the P2X3 receptor is mainly expressed in non-peptidergic C-fibre neurons and neurons with unmyelinated or small-calibre fibres. Co-localization of P2X3 receptor with Epac and PKCε supports the idea that chronic morphine increases P2X3 receptor expression through the Epac-PKCε pathway.
The P2X3 receptor is mainly expressed in nociceptive sensory neurons in the DRG and plays vital roles in sensory processing and transmission (Wirkner et al., 2007) . ATP is released from different cell types around primary sensory neurons, especially under conditions of pathological pain (Burnstock, 2000) . Evidence has emerged that the P2X3 receptor participates in models of chronic pain. Inhibition of P2X3 receptor expression has been reported to alleviate neuropathic pain (Xu et al., 2012) and reverse mechanical hyperalgesia (Brown and Yule, 2007) . Prado et al. (2013) suggested that neuronal P2X3 receptor activation and the consequent PKCε translocation increase the susceptibility of nociceptors to inflammatory mediators, allowing the development of inflammatory hyperalgesia. Our previous behavioural experiments in mice showed that an antagonist of P2X3 receptor delays the development of morphineinduced analgesic tolerance (Ma et al., 2010) . But the details of the involvement of P2X3 receptor in such tolerance remained unclear. Here, we demonstrated that expression of P2X3 receptor increases during the development of morphine-induced anti-nociceptive tolerance in rats.
Among the three types of P2X current induced by ATP in adult rat DRG neurons, the fast currents mainly occur in small IB4-positive DRG neurons (Grubb and Evans, 1999) , and the intracellular signalling pathway for the activation of PKCε (Epac/PLC/PKCε) is also closely correlated with the subtype of small DRG neurons expressing IB4 (Hucho et al., 2005) . Our results here showing the co-localization of P2X3 receptor with IB4 in DRG neurons. And the colocalization of P2X3 receptor with peripherin showed that the P2X3 receptor is mainly expressed in neurons with unmyelinated or small-calibre fibres. Epac-PKCε signalling may be responsible for chronic morphine-induced P2X3 receptor expression. Epac has been reported to play a key role in the activation of PKCε in DRG neurons (Hucho et al., 2005; Wang et al., 2007) . Epac-PKCα signalling in P2X3 receptor-mediated hyperalgesia after inflammation was proposed by Gu et al. (2016a) , and it has been reported that an Epac-PKC-dependent increase in F-actin in DRG neurons enhances the membrane expression of P2X3 receptor to bring about their sensitization after inflammation (Gu et al., 2016b) . The participation of PKCε in receptor desensitization and morphine-induced tolerance has been extensively reported (Chu et al., 2010) . PKCε activation has been reported to modulate the heterologous regulation of μ-opioid receptor phosphorylation (Illing et al., 2014) and play an important role in the development of morphine-induced tolerance (Qiu et al., 2014) . Consistent with these studies, our results showed a robust increase in PKCε phosphorylation after long-term morphine exposure. Co-administration of ε-V1-2, a PKCε-specific inhibitor, along with morphine clearly delayed the development of morphine-induced antinociceptive tolerance. Meanwhile, this inhibitor effectively inhibited the chronic morphine-induced increase of P2X3 receptor expression in the rat DRG. Co-localization of P2X3 receptor with PKCε provides strong evidence that the morphine-induced increased expression of P2X3 receptor can be suppressed by reducing the PKCε phosphorylation in the same neuron. Phosphorylation of PKCε in DRGs could be regarded as an upstream target of P2X3 receptor expression during the development of chronic morphine-induced analgesic tolerance. Epac is known to be up-regulated in inflammation and to play a critical role in P2X3 sensitization by activation of PKCε-dependent signalling via PGE 2 (Wang et al., 2007) . Gu et al. (2016b) showed that F-actin links Epac-PKCε signalling to P2X3 receptor sensitization in the DRG in inflammation. Another work by this group also showed that Epac plays an essential role in the P2X3 receptor-mediated hyperalgesia in inflammation (Gu et al., 2016a) . However, there is no previous work exploring the role of Epac in the development of morphine-induced anti-nociceptive tolerance. Here, we showed that chronic morphine exposure increased the expression of Epac in DRGs. Pretreatment with ESI-09, a specific Epac inhibitor, not only decreased chronic morphine-induced P2X3 receptor expression but also reduced repeated morphine-induced PKCε phosphorylation. In behavioural tests, rats pretreated with the Epac inhibitor showed resistance to morphine anti-nociceptive tolerance Mor tolerance was attenuated when Mor was administered with ε-V1-2 for 7 days (n = 6,*P < 0.05 vs. saline (S) group; # P < 0.05 vs. morphine group).
M3, 3 days of morphine injection; M5, 5 days of morphine injection; M7, 7 days of morphine injection.
after repeated treatment. The co-localization of P2X3 receptor with Epac provides a basis for this chronic morphineinduced signalling process to occur in the same neuron during the establishment of anti-nociceptive tolerance. Activation of P2X3 receptor within the CASK/P2X3 complex has important consequences for neuronal plasticity (Fabbretti, 2013) and possibly for the release of neuromodulators and neurotransmitters that may accelerate the formation of morphine-induced analgesic tolerance. P2X3-positive neurons belong almost exclusively to the GDNF-sensitive population (Bradbury et al., 1998) , and 75% of P2X3-positive neurons contain TRPV1 (Guo et al., 1999) . Involvement of TRPV1 in morphine-induced effects has been reported (Chen et al., 2007; Vardanyan et al., 2009 ). Besides co-localization, the P2X3 receptor and TRPV1 may functionally interact, which suggests that the two pain-relevant receptors P2X3 and TRPV1 probably interact in an inhibitory manner by a close physical association that is established by means of a structural motif located at the C-terminal end of the P2X3 receptor distal to Glu 362 (Stanchev et al., 2009 ). This evidence also indicates a possible role of P2X3 receptor in the development of morphine-induced analgesic tolerance. As morphine-induced analgesic tolerance is considered to lead to neuroimmune activation and neuroinflammation (Raghavendra et al., 2002; DeLeo et al., 2004) , the upregulation of P2X3 receptor during morphine-induced analgesic tolerance maybe a consequence of the activation of Epac-PKCε signalling, morphine-induced sensitization and Epac-PKCε signal and P2X3 receptor in morphine tolerance neuronal inflammation. We did not evaluate neuroinflammation during the chronic morphine exposure and its relationship with Epac-PKCε signalling and P2X3 receptor sensitization. Such data would be an important supplement to this work. The mediation of P2X3 receptor via Epac-PKCε signalling could be an effective target to alleviate chronic morphine-induced anti-nociceptive tolerance.
